Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Xilio Therapeutics, Inc. (Nasdaq: XLO) is a clinical-stage biotechnology company developing tumor-activated, or masked, immuno-oncology therapies for people living with cancer. The XLO news feed on Stock Titan aggregates company-issued press releases and related coverage so readers can follow how Xilio’s pipeline, collaborations and financial position evolve over time.
News about Xilio frequently centers on clinical and preclinical data from its key programs. These include vilastobart, an investigational tumor-activated, Fc-enhanced anti-CTLA-4 antibody being studied in combination with atezolizumab in advanced solid tumors and microsatellite stable metastatic colorectal cancer, and efarindodekin alfa (XTX301), a tumor-activated IL-12 in a Phase 1/2 trial for advanced solid tumors. The company also reports on progress for XTX501, a bispecific PD-1 / masked IL-2 molecule in IND-enabling studies, and multiple masked T cell engager programs targeting tumor-associated antigens such as PSMA, CLDN18.2 and STEAP1.
Investors can use this page to track Xilio’s announcements about clinical trial milestones, data presentations at scientific meetings like the Society for Immunotherapy of Cancer (SITC) and the American Society of Clinical Oncology (ASCO), and updates on collaborations with partners including Gilead, Roche and AbbVie. The feed also captures corporate developments such as financings, warrant exercises, cash runway guidance, stock option plans and board or leadership changes disclosed in press releases and related SEC filings.
By reviewing the XLO news stream, readers gain a consolidated view of how Xilio’s masked immunotherapy platform is progressing through research and development, how external partners are engaging with its programs, and how the company is addressing Nasdaq listing requirements and capital needs as it advances its oncology pipeline.
Xilio Therapeutics, Inc. (Nasdaq: XLO) reported significant progress in its clinical pipeline and financial results for 2021. The company has $198.1 million in cash, ensuring operational continuity into 2024. Key developments include anticipated initial Phase 1 data readouts for XTX101 and XTX202 in 2022, along with plans to submit an IND for XTX301. Research and Development (R&D) expenses rose to $51.2 million for 2021, primarily due to increased personnel costs. Xilio ended the year with a net loss of $75.8 million.
Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology firm focusing on tumor-selective immuno-oncology therapies, announced that CEO René Russo will participate in the "Novel IO Panel" at the Cowen 42nd Annual Healthcare Conference on March 7, 2022, at 10:30 a.m. ET. The event will be available via live webcast on the company’s website, with a replay accessible for 30 days post-presentation. Xilio aims to enhance cancer treatment using its proprietary GPS platform to create targeted biologics, including several promising therapeutic candidates.
Xilio Therapeutics, Inc. (Nasdaq: XLO) will host a virtual fireside chat at the Guggenheim 4th Annual Oncology Day on February 10, 2022, at 8:30 a.m. ET. The event will feature CEO René Russo and CMO Marty Huber discussing the company’s tumor-selective immuno-oncology therapies. A live webcast will be accessible via Xilio’s website, and a replay will be available for 30 days post-event. Xilio is dedicated to developing innovative cancer treatments utilizing its proprietary GPS platform, focusing on tumor-localized biologics aimed at enhancing anti-tumor activity.
Xilio Therapeutics (Nasdaq: XLO) announced the first patient has been dosed in its Phase 1/2 clinical trial for XTX202, an innovative IL-2 therapy aimed at treating solid tumors. Designed to target the tumor microenvironment (TME), XTX202 aims to enhance anti-tumor effects while minimizing toxicity compared to existing IL-2 therapies. The trial will assess safety, tolerability, and effectiveness in patients with advanced solid tumors, setting the stage for further investigations in larger, more diverse cohorts.
Xilio Therapeutics, Inc. (Nasdaq: XLO) appointed Dr. Yuan Xu to its board of directors. Dr. Xu brings over 25 years of experience in the biopharmaceutical industry, having previously served as CEO at Legend Biotech and senior VP at Merck. Her leadership is expected to be crucial as Xilio advances its tumor-selective immuno-oncology therapies, with data readouts for two programs anticipated in 2022. Dr. Xu emphasized the importance of Xilio’s mission to develop therapies that minimize toxicity while maximizing effectiveness, including product candidates XTX101 and XTX202.
Xilio Therapeutics (Nasdaq: XLO) reported significant advancements in its clinical pipeline and financial results for Q3 2021. The company plans to initiate a Phase 1/2 trial for XTX202, a tumor-selective IL-2, in Q1 2022. After a successful IPO in October 2021, raising approximately $130 million, Xilio is well-positioned to enhance its tumor-selective immuno-oncology therapies. However, net losses increased to $16.3 million from $14.8 million year-over-year. R&D expenses decreased, while G&A expenses rose, reflecting growth in headcount and professional services.
Xilio Therapeutics, Inc. (Nasdaq:XLO) announced promising preclinical results for XTX301, a tumor-selective engineered interleukin-12 (IL-12) candidate, at the Society for Immunotherapy in Cancer’s Annual Meeting. The data demonstrate selective anti-tumor activity with minimal systemic effects, indicating potential for optimized therapeutic index. In animal models, XTX301 achieved up to 90% tumor growth inhibition and showed excellent tolerability in non-human primates. Xilio plans to file an investigational new drug application for XTX301 with the FDA in H2 2022.
Xilio Therapeutics, a biotechnology firm specializing in tumor-selective immuno-oncology therapies, has successfully closed its initial public offering (IPO) of 7,353,000 shares at $16.00 each, raising approximately $117.6 million before expenses. The shares started trading on the Nasdaq under the ticker symbol XLO on October 22, 2021. Underwriters also received an option to purchase up to 1,102,950 additional shares. The company aims to leverage these proceeds to advance its proprietary GPS platform and pipeline of anti-cancer therapies.